<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153215">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02138890</url>
  </required_header>
  <id_info>
    <org_study_id>BBI.CR.APS1.14</org_study_id>
    <nct_id>NCT02138890</nct_id>
  </id_info>
  <brief_title>APSS-33-00: A Multicenter, Pilot Study of Autologous Protein Solution (APS) in Knee Osteoarthritis (OA)</brief_title>
  <acronym>APSS-33-00</acronym>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study of a Single, Intra-Articular Injection of Autologous Protein Solution (APS) in Patients With Osteoarthritis (OA) of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomet, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biomet, Inc.</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Austria: Ethikkommission</authority>
    <authority>Norway: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind, multicenter, randomized, controlled trial (RCT) will evaluate the
      efficacy of a single dose of Autologous Protein Solution (APS) in patients with
      osteoarthritis (OA) of the knee who have failed at least 1 conservative osteoarthritis (OA)
      therapy (e.g. physiotherapy, simple analgesics, intra-articular injection).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, multicenter, randomized, controlled trial (RCT) that will evaluate the
      efficacy of a single dose of Autologous Protein Solution (APS) in patients with
      Osteoarthritis (OA) of the knee who have failed at least 1 conservative OA therapy (e.g.
      physiotherapy, simple analgesics, intra-articular injection).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual Analogue Scale - Pain</measure>
    <time_frame>6 Month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pain will be measured utilizing patient surveys</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score - Function</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Knee function will be measured utilizing patient surveys and knee examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score - Stiffness</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Knee stiffness will be measured utilizing patient surveys and knee examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Imaging - Joint Structure</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Joint structure will be examined radiographically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaires (QoL)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QoL will be assessed utilizing Quality of Life questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events (Safety)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>APS injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Protein Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>APS</intervention_name>
    <description>Intra-articular Injection</description>
    <arm_group_label>APS injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intra-articular injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥40 years and ≤75 years.

          -  Willingness and ability to comply with the study procedures and visit  schedules and
             ability to follow verbal and written instructions.

          -  Diagnosis of knee osteoarthritis (OA) Grade 2 or 3 according to the Kellgren-Lawrence
             scale

          -  Body mass index (BMI) ≤ 40.

          -  Failed at least 1 conservative OA therapy

          -  Signed an independent ethics committee (IEC) approved informed consent form (ICF).

        Exclusion Criteria:

        - Intra-articular Hyaluronic (HA) injection within 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Kon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bologna (Italy)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cahit Akbas</last_name>
    <phone>+31 6 229 817 37</phone>
    <email>cahit.akbas@biomet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Krems Hospital</name>
      <address>
        <city>Krems</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S. Nehrer, MD</last_name>
    </contact>
    <investigator>
      <last_name>S. Nehrer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monica Hospitals</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. Verdonk, MD</last_name>
    </contact>
    <investigator>
      <last_name>P. Verdonk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rizzoli Orthopaedic Institute</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E. Kon, MD</last_name>
    </contact>
    <investigator>
      <last_name>E. Kon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L. Engrebretsen, MD</last_name>
    </contact>
    <investigator>
      <last_name>L. Engebretsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>May 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous Protein Solution</keyword>
  <keyword>APS</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Intra Articular Injection</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
